Citations

Clear

7732 citation(s) found for "Ma, Daniel".

Expression of a potential metastasis suppressor gene (nm23) in thyroid neoplasms
Farley, David R. , Eberhardt, Norman L., Grant, Clive S., Schaid, Daniel J. , Heerden, Jonathan A. van, Khosla, Sundeep , Hay, Ian , Khosla, Sundeep

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 17 | Issue: 5 | Pages: 615-620

10.1007/bf01659123 | PMID 8273382 Get It

AbstractIdentification of multiple clinical and pathologic prognostic factors in differentiated thyroid cancer has permitted some degree of risk stratification. However, these clinical indices fail to distinguish potential intrinsic differences in tumor virulence. The nm23 gene has been identified as a potential metastasis suppressor gene that is homologous to nucleoside diphosphate kinases. Studies in human breast cancer have shown a significant inverse correlation between nm23 levels and nodal involvement/tumor recurrence. Given the possible clinical utility of a marker of metastatic potential in the management of thyroid carcinoma, we examined 34 thyroid neoplasms and a human medullary thyroid cancer (MTC) cell line (TT) for nm23 expression. Normalized nm23 expression was assessed by Northern analysis of tumor RNA. nm23 Expression (tumor expression/TT cell expression, mean ±SE) was 1.14 ±0.15* in MTCs (n =5), 0.70 ±0.10* in follicular cancers (n=6), 0.51 ±0.11 in papillary cancers (n=19), and 0.31 ±0.03 in follicular adenomas (n=4) (*p< 0.05 when compared to adenomas). Within histologicgroups, we found no correlation between nm23 expression and nodal involvement or distant métastases. Our results indicate that thyroid neoplasms of different histologies express varying levels of the nm23 transcript. Although nm23 expression seems diminished in metastatic breast cancer, it appears not to be the case in metastatic thyroid cancer. The nm23 gene may therefore have different roles in the evolution and metastases of different neoplasms.
Physiological Role for the Cochaperone FKBP52 in Androgen Receptor Signaling
Cheung‐Flynn, Joyce , Prapapanich, Viravan, Cox, Marc B. , Suárez‐Quian, Carlos A. , Riggs, Daniel L. , Smith, David F.

Mayo Clinic

Molecular Endocrinology | April 15, 2005 | Volume: 19 | Issue: 6 | Pages: 1654-1666

10.1210/me.2005-0071 | PMID 15831525 Get It

AbstractMolecular chaperones mediate multiple aspects of steroid receptor function, but the physiological importance of most receptor-associated cochaperones has not been determined. To help fill this gap, we targeted for disruption the mouse gene for the 52-kDa FK506 binding protein, FKBP52, a 90-kDa heat shock protein (Hsp90)-binding immunophilin found in steroid receptor complexes. A mouse line lacking FKBP52 (52KO) was generated and characterized. Male 52KO mice have several defects in reproductive tissues consistent with androgen insensitivity; among these defects are ambiguous external genitalia and dysgenic prostate. FKBP52 and androgen receptor (AR) are coexpressed in prostate epithelial cells of wild-type mice. However, FKBP52 and AR are similarly coexpressed in testis even though testis morphology and spermatogenesis in 52KO males are usually normal. Molecular studies confirm that FKBP52 is a component of AR complexes, and cellular studies in yeast and human cell models demonstrate that FKBP52 can enhance AR-meditated transactivation. AR enhancement requires FKBP52 peptidylprolyl isomerase activity as well as Hsp90-binding ability, and enhancement probably relates to an affect of FKBP52 on AR-folding pathways. In the presence of FKBP52, but not other cochaperones, the function of a minimally active AR point mutant can be dramatically restored. We conclude that FKBP52 is an AR folding factor that has critically important physiological roles in some male reproductive tissues.
Mapping Sites of Protein Phosphorylation by Mass Spectrometry Utilizing a Chemical-Enzymatic Approach:  Characterization of Products from α-S1Casein Phosphopeptides
Muddiman, David C. , McCormick, Daniel , Holmes, Michael W.R. , Madden, Benjamin J.

Mayo Clinic

Journal of Proteome Research | April 11, 2005 | Volume: 4 | Issue: 2 | Pages: 424-434

10.1021/pr049804u | PMID 15822919 Get It

Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials
Sargent, Daniel J. , Conley, Barbara A. , Allegra, Carmen J. , Collette, Laurence , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | March 18, 2005 | Volume: 23 | Issue: 9 | Pages: 2020-2027

10.1200/jco.2005.01.112 | PMID 15774793 Get It

Current staging and risk-stratification methods in oncology, while helpful, fail to adequately predict malignancy aggressiveness and/or response to specific treatment. Increased knowledge of cancer biology is generating promising marker candidates for more accurate diagnosis, prognosis assessment, and therapeutic targeting. To apply these exciting results to maximize patient benefit, a disciplined application of well-designed clinical trials for assessing the utility of markers should be used. In this article, we first review the major issues to consider when designing a clinical trial assessing the usefulness of a predictive marker. We then present two classes of clinical trial designs: the Marker by Treatment Interaction Design and the Marker-Based Strategy Design. In the first design, we assume that the marker splits the population into groups in which the efficacy of a particular treatment will differ. This design can be viewed as a classical randomized clinical trial with upfront stratification for the marker. In the second design, after the marker status is known, each patient is randomly assigned either to have therapy determined by their marker status or to receive therapy independent of marker status. The predictive value of the marker is assessed by comparing the outcome of all patients in the marker-based arm to that of all of the patients in the non–marker-based arm. We present detailed sample size calculations for a specific clinical scenario. We discuss the advantages and disadvantages of the two trial designs and their appropriateness to specific clinical situations to assist investigators seeking to design rigorous, marker-based clinical trials.
Current Indications for the Use of The Artificial Genitourinary Sphincter and Management of It's Complications
Elliott, Daniel S. , Barrett, David M.

Mayo Clinic

The Scientific World JOURNAL | March 16, 2005 | Volume: 4 | Issue: No issue available | Pages: 114-127

10.1100/tsw.2004.57 | PMID 29861669 Get It

Determinants of Dual Secretagogue Drive of Burst-Like Growth Hormone Secretion in Premenopausal Women Studied under a Selective Estradiol Clamp
Erickson, Dana , Keenan, Daniel M., Farhy, Leon S. , Mielke, Kristi L., Bowers, Cyril Y., Veldhuis, Johannes D.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 9, 2005 | Volume: 90 | Issue: 3 | Pages: 1741-1751

10.1210/jc.2004-1621 | PMID 15613434 Get It

Early origins of polycystic ovary syndrome
Dumesic, Daniel A. , Schramm, R. Dee, Abbott, David H.

Mayo Clinic

Reproduction, Fertility and Development | February 15, 2005 | Volume: 17 | Issue: 3 | Pages: 349-360

10.1071/rd04092 | PMID 15745643 Get It

The prenatally androgenised female rhesus monkey has become a model for polycystic ovary syndrome (PCOS) in women, with early prenatal androgenisation entraining a permanent PCOS-like phenotype characterised by luteinising hormone (LH) hypersecretion due to reduced hypothalamic sensitivity to steroid negative feedback and relative insulin excess associated with increased abdominal adiposity. These combined reproductive and metabolic abnormalities occur in combination with ovarian hyperandrogenism and follicular arrest in adulthood, and with premature follicle differentiation and impaired embryo development during gonadotrophin therapy for in vitro fertilization (IVF). The ability of prenatal androgen excess in fetal rhesus monkeys to entrain multiple organ systems in utero provides evidence that the hormonal environment of intrauterine life programmes target tissue differentiation, raising the possibility that hyperandrogenism in human fetal development promotes PCOS in adulthood. This hypothesis developed in prenatally androgenised female rhesus monkeys, however, also must include data from clinical studies of PCOS to clarify the homology between human and non-human primates in intrafollicular steroidogenesis and its impact on oocyte developmental competency. By doing so, future studies promise to develop new clinical strategies that will lead to improved pregnancy outcome and reduced pregnancy loss in women with disorders of insulin action, including PCOS, obesity and diabetes mellitus.
Phase II Study of 5-fluorouracil, Doxorubicin, and Mitomycin C for Metastatic Small Bowel Adenocarcinoma
Holcroft, Christina, Kvols, Larry K., Haller, Daniel G. , Gibson, Michael K.

Mayo Clinic

The Oncologist | February 11, 2005 | Volume: 10 | Issue: 2 | Pages: 132-137

10.1634/theoncologist.10-2-132 | PMID 15709215 Get It

Abstract Background. Small bowel adenocarcinoma is a rare gastrointestinal malignancy that is treated primarily with surgery. Even with optimal resection, however, survival is poor and recurrences are common. Response rates to palliative combination chemotherapy are low, and the median duration of survival for metastatic disease is less than 1 year. This study aimed to document the response rate and survival time for patients with advanced small bowel adenocarcinoma who were not surgically curable and were treated with a regimen of 5-fluorouracil (5-FU), mitomycin C (Mutamycin®; Bristol-Myers Squibb; Princeton, NJ), and doxorubicin (Adriamycin®; Bedford Laboratories; Bedford, OH), the FAM regimen. Methods. This multi-institutional study was performed by the Eastern Cooperative Oncology Group (ECOG). Between November, 1983 and December, 1985, 39 patients with advanced or recurrent disease were enrolled. Chemotherapy was given as follows: 5-FU, 600 mg/m2 on days 1, 8, 29 and 36; mitomycin C, 10 mg/m2 on day 1; and doxorubicin, 30 mg/m2 on days 1 and 29. Eligibility criteria included an ECOG performance status score of 0–2, measurable disease, and adequate baseline organ function. Prior chemotherapy was allowed. Response was measured by examination and imaging techniques. Survival time and time to progression were evaluated by the method of Kaplan and Meier, and these outcomes were stratified by clinical and laboratory covariates. Results. Of the 39 evaluated patients, 38 were eligible and 36 were evaluable for response. Grade 3–5 toxicities were experienced by a total of 26 patients (20 grade 3, 5 grade 4, 1 grade 5). The most common adverse events were neutropenia and vomiting. Responses were seen in a total of seven patients (2 complete responses, 5 partial responses), for a response rate of 18.4% (95% confidence interval of 7.8%–34.4%). The median survival time was 8 months. Conclusions. The FAM regimen was active and tolerable for patients with advanced small bowel adenocarcinoma; however, the results were no better than those seen with other chemotherapy combinations.
Thyroid Function Inside and Outside of Pregnancy: What Do We Know and What Don't We Know?
Smallridge, Robert C., Glinoer, Daniel, Hollowell, Joseph G., Brent, Gregory A.

Mayo Clinic

Thyroid | February 1, 2005 | Volume: 15 | Issue: 1 | Pages: 54-59

10.1089/thy.2005.15.54 | PMID 15687824 Get It

In Reply:
Crane, Christopher H. , Sargent, Daniel J. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | January 29, 2005 | Volume: 23 | Issue: 4 | Pages: 934-935

10.1200/jco.2005.05.298 Get It